- Home
-
Technical Platform
-
Services
- TCR-T Lead Sequence Development Service
- Immune CAR Cell Preparation Technology Service
- Antibody Coupled Drug Discovery Service
- Antibody Affinity Maturation Service
- Antibody Humanization Services
- Bispecific Antibody Development Services
- Antibody Protein Sequencing Service
- Antibody Affinity Determination Service
Antibody Drugability Assessment
- Nucleic Acid Aptamer Synthesis Service
- Nucleic Acid Aptamer Modification Service
- Nucleic Acid Aptamer Library Construction Service
- Bispecific Aptamer Development Service
- Protein Nucleic Acid Aptamer Screening Service
- Metal Ion Nucleic Acid Aptamer Screening Service
- Small Molecule Nucleic Acid Aptamer Screening Service
- Cell Nucleic Acid Aptamer Screening Service
- Targeted Peptide Library Screening Service
- Targeted Peptide Library Construction Service
Active Peptide Discovery Technology Service
- mRNA Immune Antibody Preparation Service
- DNA Immune Antibody Preparation Service
Animal Immunization Technology Services
-
Technical Support
- Structural Basis for Selectivity and Antagonism in GPCR-Nanobodies
- Novel Peptide-Drug Conjugate (PDC) Shows Efficacy in Hepatocellular Carcinoma Models
- Nanobody Expression in Insect Cells
- Nanobody Mammalian Cell Expression
- Single-chain Antibody Library Construction Technology Introduction
- Prokaryotic Expression of Nanobodies
- Cell Line Immunogen of Nanobody
- Construction of Single Chain Antibody Library
- Nano-antibody/Single Domain Antibody Library Construction Service
- Customized Nano-antibody Immunogen3
- Novel Cancer Therapeutic Strategy: Development of Bispecific Antibody-Drug Conjugates
- Nveiling the Molecular and Immunological Drivers of Antibody-Drug Conjugates (ADCs) in Cancer Treatment
- A PBD Dimer-Containing Antibody-Drug Conjugate (KK2845) Targeting TIM-3-Expressing AML
- A Novel Approach for Cancer Therapy - Modulating TCR Complex Recruitment to the T Cell Antigen Coupler (TAC) Enhances TAC-T Cell Function
- Development of Therapeutic Monoclonal Antibodies for Disease Treatment
- Common Problems and Solutions of Prokaryotic Expression of Recombinant Protein
- Neutralizing Monoclonal Antibody Development Service FAQ
- A Brief Discussion on Prokaryotic Expression of Recombinant Antibodies
- Common Problems and Solutions for Recombinant Antibody Yeast Expression Experiments
- Common Problems and Solutions for Recombinant Antibody Expression Experiments in lactation
Special topic on antibody modification
- Common Problems and Solutions for Yeast Two-hybrid Experiments
- Yeast Two-hybrid Technique Related Issues
- Common Problems and Solutions of Yeast Display Technology
- Overview of Yeast Two Hybrid System Principle and Application
- Introduction to Yeast Display Antibody Screening Technology
- Overview of Yeast Display Technology
- Overview of Yeast Two Hybrid Technology
- Yeast Display Platform for Rapid Nanobody Discovery
- What is the essential difference between antibody phage display and yeast display?
- Yeast One Hybrid FAQ
Yeast Display Technology Special Topic
- New Molecular Interaction Technology: How Much Do You Know About Yeast Hybridization Technology?
- Antibody Affinity Testing(SPR)
- Hybridoma Gene Sequencing Process
- Antibody Affinity Detection (BLI)
- Antibody Affinity Test EC50
- Antibody Full Length Sequencing
Antibody Detection Service Topic
- Novel Targeted Tumor Therapeutics: Efficacy of a Peptide-Drug Conjugate (PDC) in a Hepatocellular Carcinoma Model
- Non-Invasive In Vivo Monitoring of PROTAC-Mediated Protein Degradation Using an Environment-Sensitive Reporter
- How do you know Phage Display Peptide Library?
- Phage Display Peptide Library
- Phage Display Antibody Library Technology
- Efficient Screening Methods and Research Progress of Anti-tumor Polypeptides
- Molecular Screening and Application of Targeted Peptides
- Screening Strategies for Cyclic Peptide Drugs
- Construction Method of Random Peptide Library
- Construction and Screening of Peptide Library
Special Topic on Phage Display Technology
- A Promising Novel Cancer Therapeutic Strategy: Aptamer-Drug Conjugates (ApDCs)
- A Novel Therapeutic Approach for Multiple Myeloma: Development of a CD38 and CD47 Bispecific Bipartopic Antibody
- A Novel Therapeutic Approach - CAR-M
- Application And Prospects of CAR-T Technology in Tumor Immunotherapy
- CAR-T Discovery Service
CAR-T Molecule Discovery Topic
- The Promise of Small Nucleic Acid Therapeutics: From Bench to Clinic as Next-Generation Medicines
- Issues Related to Aptamer Library Screening
- Introduction to Nucleic Acid Aptamer Library Screening Technology
- Overview of Aptamer Synthesis Technology
- Screening and optimization of nucleic acid aptamers
- Screening and Application of Peptide Aptamers
- Main Research Directions Progress and Challenges of Nucleic Acid Aptamer Screening Technology
- Research Progress of Protein Nucleic Acid Aptamer Screening
- Research Progress of Aptamer Screening-of Small Molecule Targets
- Nucleic Acid Aptamer Libraries Screening: an Efficient Method for Discovering Specific Binding Molecules
Molecular Biology Service Topics
-
Product Center
- Contact Us
Product Center
About US
-
Phone
400-168-8285 -
Email
info@tekbiotech.com -
Address
Building A5, International Enterprise Community, Wuqing, Tianjin
Inquiry and ordering
Nanobody Related Reagent
Known for its advanced technology platform and strict quality control system, TekBitech provides comprehensive antibody research solutions for research institutions and biotechnology companies. Nanobody reagents have smaller molecular weights and excellent binding properties, making them suitable for studies of complex biological samples and giving scientists powerful experimental tools. At the same time, camelid secondary antibodies, due to their unique antigen-binding properties, show broad application prospects in biomedical research and biotechnology applications. TekBiotech continuously innovates, constantly advancing the field of antibody discovery and making significant contributions to the global life sciences.
Nanobody Related Reagent IntroductionAlpaca Total IgG(IgG1+IgG2+IgG3)
Datasheet
- TKPA101
- Alpaca IgG Native Protein, alpaca control antibody, alpaca isotype control
- 1mg,5mg,10mg
Goat Anti-Alpaca IgG1+IgG2+IgG3 Antibody
Datasheet
- TKPA102
- Goat anti alpaca IgG, Anti-Alpaca Secondary Antibodies
- 20ul,50ul,100ul
Goat Anti-Camel IgG1+IgG2+IgG3 Antibody
Datasheet
- TKPA103
- Goat anti camel IgG, Anti-Camel Secondary Antibodies
- 20ul,50ul,100ul
Rabbit Anti-Alpaca VHH Antibody
Datasheet
- TKPA104
- Camelid VHH Antibody, Anti-Alpaca Secondary Antibodies
- 20ul,50ul,100ul
Alpaca IgG2
Datasheet
- TKPA105
- Alpaca IgG2 Native Protein, IgG2, Alpaca Immunoglobulin Isotype-2, alpaca control antibody, alpaca isotype control
- 1mg,5mg,10mg
Alpaca IgG3
Datasheet
- TKPA106
- Alpaca IgG3 Native Protein, IgG3, Alpaca Immunoglobulin Isotype-3, alpaca control antibody, alpaca isotype control
- 1mg,5mg,10mg
Alpaca VHH
Datasheet
- TKPA107
- Alpaca single domain antibody, Variable domain of heavy chain of heavy-chain antibody, sdAb
- 0.1mg,0.5mg,1mg
Alpaca IgG1
Datasheet
- TKPA108
- Alpaca IgG1 Native Protein, IgG1, Alpaca Immunoglobulin Isotype-1, alpaca control antibody, alpaca isotype control
- 1mg,5mg,10mg
Rabbit Anti-Alpaca IgG1 Antibody
Datasheet
- TKPA109
- Rabbit anti alpaca IgG1, Anti-Alpaca Secondary Antibodies
- 20ul,50ul,100ul
Rabbit Anti-Alpaca IgG2 Antibody
Datasheet
- TKPA110
- Rabbit anti alpaca IgG2, Anti-Alpaca Secondary Antibodies
- 20ul,50ul,100ul
To experience the reliable service of Tekbiotech please subscribe:
-
Antibody Discovery
-
Antibody Production
-
Antibody Modification
Contact
- Phone：400-168-8285
- Email：info@tekbiotech.com
- Address：Building A5, International Enterprise Community, Wuqing, Tianjin
Follow us!
Technical Support
©2026Tekbiotech (Tianjin) Co., Ltd